EconPapers    
Economics at your fingertips  
 

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

Sunhwa Kim, Hiroyuki Takahashi, Wan-Wan Lin, Pascal Descargues, Sergei Grivennikov, Youngjun Kim, Jun-Li Luo and Michael Karin ()
Additional contact information
Sunhwa Kim: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Hiroyuki Takahashi: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Wan-Wan Lin: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Pascal Descargues: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Sergei Grivennikov: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Youngjun Kim: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Jun-Li Luo: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA
Michael Karin: School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0723, USA

Nature, 2009, vol. 457, issue 7225, 102-106

Abstract: Versican drives metastasis Distant-site metastases are the leading cause of cancer-associated mortality. A study of the inflammatory microenvironment of cancer cells has identified versican, an extracellular matrix proteoglycan, as a possible factor in driving metastasis. It was isolated from the highly metastatic Lewis lung carcinoma cells as a potent inducer of macrophage activation. Versican, which is upregulated in many human tumours, stimulates bone marrow cells via the Toll-like receptor TLR2 to produce the inflammatory protein TNF-?, which enhances the spread of metastases. This points to versican and the other components of this signalling pathway as potential targets for antimetastatic intervention.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature07623 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:457:y:2009:i:7225:d:10.1038_nature07623

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07623

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:nature:v:457:y:2009:i:7225:d:10.1038_nature07623